Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Wadden TA, et al. Among authors: billings lk. JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831. JAMA. 2021. PMID: 33625476 Free PMC article. Clinical Trial.
An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
Evans M, Billings LK, Håkan-Bloch J, Slothuus U, Abrahamsen TJ, Andersen A, Jansen JP. Evans M, et al. Among authors: billings lk. J Med Econ. 2018 Apr;21(4):340-347. doi: 10.1080/13696998.2017.1409228. Epub 2017 Dec 3. J Med Econ. 2018. PMID: 29164973 Free article. Clinical Trial.
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
Philis-Tsimikas A, Billings LK, Busch R, Portillo CM, Sahay R, Halladin N, Eggert S, Begtrup K, Harris S. Philis-Tsimikas A, et al. Among authors: billings lk. Diabetes Obes Metab. 2019 Jun;21(6):1399-1408. doi: 10.1111/dom.13666. Epub 2019 Apr 4. Diabetes Obes Metab. 2019. PMID: 30761720 Free PMC article. Clinical Trial.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Del Prato S, et al. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.
Miller E, Doshi A, Grøn R, Jódar E, Őrsy P, Ranthe MF, Sugimoto D, Tentolouris N, Viljoen A, Billings LK. Miller E, et al. Among authors: billings lk. Diabetes Obes Metab. 2019 Dec;21(12):2643-2650. doi: 10.1111/dom.13851. Epub 2019 Aug 28. Diabetes Obes Metab. 2019. PMID: 31385425 Free PMC article. Clinical Trial.
Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.
Janez A, Őrsy P, Stachlewska K, Salvesen-Sykes K, Billings LK, Philis-Tsimikas A. Janez A, et al. Among authors: billings lk. Diabetes Obes Metab. 2020 Apr;22(4):658-668. doi: 10.1111/dom.13944. Epub 2020 Jan 27. Diabetes Obes Metab. 2020. PMID: 31858673 Free PMC article. Clinical Trial.
The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
Billings LK, Agner BFR, Altuntas Y, Grøn R, Halladin N, Klonoff DC, Tentolouris N, Jódar E. Billings LK, et al. J Diabetes Sci Technol. 2021 May;15(3):636-645. doi: 10.1177/1932296820906888. Epub 2020 Feb 28. J Diabetes Sci Technol. 2021. PMID: 32107930 Free PMC article. Clinical Trial.
85 results